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Status epilepticus (SE) induces rapid hyper-activation of the hypothalamo–pituitary–
adrenocortical (HPA) axis. HPA axis hyperactivity results in excess exposure to high 
levels of circulating glucocorticoids, which are associated with neurotoxicity and 
depression-like behavior. These observations have led to the hypothesis that HPA axis 
dysfunction may exacerbate SE-induced brain injury. To test this hypothesis, we used 
the mouse pilocarpine model of epilepsy to determine whether use of the glucocorticoid 
receptor antagonist RU486 can attenuate hippocampal pathology following SE. Excess 
glucocorticoid secretion was evident 1 day after SE in the mice, preceding the development 
of spontaneous seizures (which can take weeks to develop). RU486 treatment blocked 
the SE-associated elevation of glucocorticoid levels in pilocarpine-treated mice. RU486 
treatment also mitigated the development of hippocampal pathologies induced by SE, 
reducing loss of hilar mossy cells and limiting pathological cell proliferation in the dentate 
hilus. Mossy cell loss and accumulation of ectopic hilar cells are positively correlated with 
epilepsy severity, suggesting that early treatment with glucocorticoid antagonists could 
have anti-epileptogenic effects.
Keywords: rU486, mifepristone, status epilepticus, hippocampus, mossy cells
inTrODUcTiOn
Temporal lobe epilepsy (TLE) is commonly modeled by chemically inducing status epilepticus (SE) 
in rodents. SE induces widespread brain damage and neuronal restructuring, which lead to the 
onset of spontaneous seizures (epilepsy) a few weeks later. In particular, the loss of glutamatergic 
hilar mossy cells and the misplacement of newly generated dentate granule cells (DGCs) to the hilus 
(HIL) constitute key hippocampal pathologies that occur in synchrony with – or even precede – the 
development of epilepsy (1–5). Mossy cells mediate feedback inhibition of hippocampal DGCs by 
activating GABAergic basket cells (6), although direct connections between excitatory mossy cells 
and granule cells make their net contribution to dentate excitability complex (2). Ectopic granule 
cells, on the other hand, are hypothesized to destabilize the hippocampal network, promoting hyper-
excitability (2, 7). Notably, mossy cell loss and ectopic migration of granule cells positively correlate 
with epilepsy severity (8), and ablating ectopic cells reduces seizure frequency (9, 10).
The hypothalamo–pituitary–adrenocortical (HPA) axis is rapidly activated by SE, manifested 
as glucocorticoid basal hypersecretion (11). Animal studies demonstrate that exposure to excess 
glucocorticoids can be detrimental in the context of epilepsy, leading to increased brain excit-
ability (12–14) and potential damage (15). Conversely, the glucocorticoid synthesis inhibitor 
metyrapone reduces neuronal injury when given simultaneously with the SE-inducing convulsant 
kainic acid (16).
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Status epilepticus increases glucocorticoid levels, and gluco-
corticoids can damage the brain. Collectively, these data suggest 
that blockade of glucocorticoid signaling may be beneficial in 
preventing hippocampal damage following seizures. Here, we 
determined whether treatment with the glucocorticoid recep-
tor antagonist RU486, beginning 4 h after the onset of SE, can 
mitigate pathological changes associated with TLE.
MaTerials anD MeThODs
animals
All animal procedures were approved by the Institutional Animal 
Care and Use Committee of the Children’s Hospital Research 
Foundation and conform to NIH guidelines. Forty-eight 
2-month-old C57Bl/6 male mice were obtained from Charles 
River. All mice received a subcutaneous (s.c.) injection of methyl 
scopolamine nitrate (1 mg/kg) followed by 420 mg/kg pilocarpine 
(n = 32) or saline (n = 16) 15 min later (8). Three hours after 
the onset of SE, mice received two doses of diazepam (10 mg/
kg) at 15-min intervals to diminish seizure activity. Control 
animals also received diazepam. Pretreatment body weight was 
maintained using sterile Ringer’s solution s.c. to avoid potential 
SE-related dehydration. Mice treated with pilocarpine were 
monitored for behavioral seizures and the onset of SE. Only mice 
that experienced two or more convulsive seizures and exhibited 
constant behavioral seizure activity (myoclonic jerks, immobility, 
head bobbing, etc.) for 3 h were considered to be in SE and used 
in the study.
Following SE, mice were housed in a 32°C incubator over-
night. The next morning, mice were returned to their home 
cages with ad libidum food and water under a 14/10-h light/
dark cycle. The final number of SE mice (n = 14) reflects 44% 
survival of pilocarpine-treated mice. No mortality occurred in 
the saline-treated group. One hour following the last administra-
tion of diazepam, mice were randomly assigned to treatment 
with either RU486 (20 mg/kg s.c., Sigma-Aldrich, MO, USA) or 
vehicle (propylene glycol). Treatment was given every morning 
for seven consecutive days. Groups were generated as follows: (1) 
SE + vehicle (n = 6), (2) SE + RU486 (n = 8), (3) no-SE + vehicle 
(n = 8), and (4) no-SE + RU486 (n = 8). The RU486 dose was 
selected based on prior studies (17). Baseline corticosterone 
levels were measured via radioimmunoassay (MP Biomedicals, 
Orangeburg, NY, USA) using blood collected by tail nick between 
9:00 and 10:00 a.m. on days 1, 4, and 7 after SE. Beginning 4 days 
after pilocarpine or saline treatment, all mice received the first 
of three daily injections of 5-bromo-2′-deoxyuridine (BrdU; 
50 mg/kg s.c., Sigma-Aldrich) to label dividing cells (18). Mice 
were perfused with 2.5% paraformaldehyde on the eighth day, 
and brains were prepared for histological analysis (18).
rU486
RU486 is a synthetic steroid (17 beta-hydroxy-11 beta-
[4-dimethylamino phenyl] 17 alpha-[1-propynyl]estra-4,9-
dien-3-one) capable of antagonizing the glucocorticoid (doses 
5 mg/kg in rodents) (19) and progesterone (doses 1.5 mg/kg in 
rodents) (20) receptors in vitro and in vivo. It also has moderate 
androgen receptor antagonist properties in vitro (21); however, 
in vivo effects have only been noted in the testes of rats and not 
mice at repeated doses >25  mg/kg (22). RU486 is active as an 
anti-glucocorticoid at doses >5  mg/kg and readily crosses the 
blood–brain barrier at doses >10 mg/kg (23). RU486 binds GR 
in  vivo 3.7× more potently than dexamethasone (24). RU486 
is metabolized within 1–2 h following administration (half-life 
~1 h) (25). The rate of clearance was calculated as 1.5–6 L/h/kg 
in rats (data not available for mice) (22). Autoradiography studies 
in male and female rats demonstrate selective targeting of brain 
regions including the hippocampus (25). For this study, a 20-mg/
kg s.c. dose was selected based on prior work in mice, showing 
tolerability (22) and a dampening of glucocorticoid-induced 
effects in the hippocampus (17).
immunohistochemistry
Free-floating brain sections (35 μm) were used for immunohisto-
chemistry. For BrdU immunostaining, tissue was placed in 50% 
formamide and 1× sodium citrate buffer (0.3M NaCl, 0.03M 
sodium citrate) at 67°C for 2  h, followed by 30-min treatment 
with 2 N HCl at 37°C. Subsequently, tissue was incubated for 1 h 
in blocking solution (0.1% BSA, 4% NGS, 0.2% triton-X) followed 
by overnight incubation in rat anti-BrdU (1:800 AbD Serotec 
Cat# MCA2060T, RRID:AB_10015293) at 4°C. For GluR2/3 
immunostaining, tissue was incubated in the same blocking 
solution for 1 h, followed by overnight incubation in rabbit anti-
GluR2/3 (1:500 Millipore Cat# 07-598, RRID:AB_11213931). 
Biotinylated anti-rat (1:500 Vector Laboratories Cat# BA-9400, 
RRID:AB_2336202) and anti-rabbit (1:500 Vector Laboratories 
Cat# BA-1100, RRID:AB_2336201) secondary antibodies were 
used for BrdU and GluR2/3 immunostaining, respectively. This 
step was followed by incubation in ABC reagent (1:800, Vector 
Laboratories Cat# PK-7100, RRID:AB_2336827) and diam-
inobenzidine (Sigma-Aldrich) for peroxidase detection (26). 
Sections were mounted on gelatin-coated slides, co-stained with 
cresyl violet, dehydrated, and coverslipped.
cell counts
Quantification of BrdU+ and GluR2/3+ cells was done using a 
modification of the optical fractionator method as previously 
described (27). Briefly, a 1-mm thick region of dorsal hippocam-
pus (bregma −2.80 to −3.80) was sampled by examining every 
sixth section (35 μm/section; four sections/mouse). Two regions 
of interest were examined: the dentate granule cell body layer 
and the HIL (Figure  2A). The dentate granule cell body layer 
included the subgranular zone, defined as an approximately two 
cell thick region between the HIL and the cell body layer. The 
HIL encompassed the area created between the upper and lower 
blades of the dentate, but excluding the subgranular zone and the 
portion of the CA3 pyramidal cell layer that protrudes into the 
HIL (28). Stereoinvestigator 5.05 (MicroBrightfield, Williston, 
VT, USA) set up on an Olympus BX-60 microscope equipped 
with a CCD video camera (HV-C20 Hitachi, San Jose, CA, USA) 
was used for imaging and quantification. A 5× objective was used 
to trace all contours, and a 60× NA 1.35 objective was used to 
quantify all immunopositive cells located within the region of 
interest. Measured tissue thickness was ~15 μm (~50% shrinkage 
of 35-μm sections). Optical dissector height was set at 11 μm 
FigUre 1 | rU486 decreases morning baseline corticosterone in 
post-se mice. Mice show increased corticosterone morning baseline 
secretion 24 h post-SE relative to no-SE vehicle-treated mice (#p < 0.05, 
no-SE vehicle different from all other groups). RU486 treatment reduced 
baseline corticosterone secretion in SE mice when compared to SE 
vehicle-treated mice (^p < 0.05, SE vehicle different from all other groups). 
Data presented as mean ± SEM, n = 6–8 mice per group.
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with a 2-μm guard zone. Mossy cells were distinguished from 
other glutamatergic hilar neurons by their larger size (>30 μm 
diameter) (2). Estimated volumes were obtained using Cavalleri’s 
principle [sum of section areas × (15 μm × 6)] (29). Total esti-
mated cell counts per mouse were obtained by adding the number 
of counted cells in each section and multiplying by six. Final 
values are reported as density (cells per cubic millimeter).
statistical Methods
Mice were randomized to treatment groups to prevent selec-
tion bias. All immunohistochemical data were analyzed by 
two-way ANOVA, with condition (pilocarpine vs. saline) and 
treatment (RU486 vs. vehicle) as factors. Three-way repeated 
measures ANOVA was used to analyze baseline levels of plasma 
corticosterone with time (days 1, 4, and 7), treatment, and SE 
exposure as factors. Expected interactions were tested by Student 
Newman–Keuls post  hoc analysis. Statistical significance was 
set at p ≤ 0.05. Data that violated normality assumptions were 
normalized by square-root transformation. Statistica software 
was used to perform three-way repeated measures ANOVA, 
while SigmaPlot (Version 13.0, Systat Software Inc.) was used 
for other analyses.
resUlTs
rU486 Treatment reduces corticosterone 
levels Following se
Corticosterone levels were increased 1 and 4  days after 
pilocarpine-induced SE relative to no-SE + vehicle mice. RU486 
treatment was ineffective at reducing corticosterone levels at the 
1-day time point, but levels in SE +  RU486 mice were similar 
to non-SE controls (significantly lower than SE + vehicle mice) 
4  days after SE {experimental condition  ×  treatment  ×  time 
interaction [F(2,52) = 5.8019, p = 0.0053], post hoc p < 0.001} 
(Figure 1). In addition, RU486 treatment alone increased morning 
circulating corticosterone levels relative to vehicle-treated mice 
(post hoc p < 0.001) at day 1. This phenomenon has been previ-
ously observed in human and rodent studies and is thought to be 
due to the initial blockade of GR, resulting in greater amounts 
of circulating corticosterone secondary to an initial disruption 
of glucocorticoid-mediated negative feedback. At the 7-day time 
point, morning baseline corticosterone levels were statistically 
identical in all four groups.
rU486 Treatment Mitigates hilar cell 
Proliferation
Status epilepticus increased the density of BrdU+ cells in the 
dentate HIL by 17-fold in SE +  vehicle mice relative to both 
non-SE groups (post hoc p < 0.05). RU486 treatment reduced this 
increase by 35% {experimental condition × treatment interaction 
[F(1,23) =  8.619, p =  0.007], post hoc p <  0.05}. Although the 
SE + RU486 group still had significantly more BrdU+ cells/HIL 
than the non-SE groups, counts were significantly reduced relative 
to SE + vehicle mice (post hoc p < 0.05) (Figures 2B,C). RU486 
treatment alone (no-SE + RU486) had no effect on the density of 
BrdU+ hilar cells relative to the no-SE + vehicle group. Finally, 
SE also increased the density of BrdU+ cells within the dentate 
granule cell layer and subgranular zone compared to both groups 
of control mice. RU486 treatment had no effect on increased cell 
proliferation in these regions {main effect of experimental condi-
tion [F(1,23) = 24.627, p < 0.001]} (Figure 2D).
rU486 Treatment Mitigates se-induced 
Mossy cell loss
Status epilepticus produced an 88% reduction in the density of 
GluR2/3+ mossy cells in the HIL relative to control mice {main 
effect of pathology [F(1,21) = 70.448, p < 0.001]} (Figures 2E,F). 
In SE mice treated with RU486, only a 48% reduction in mossy 
cells/HIL was observed. While this reduction was still significant 
relative to non-SE groups, RU486 treatment clearly mitigated 
mossy cell loss relative to SE +  vehicle-treated mice {pathol-
ogy  ×  treatment interaction [F(1,21)  =  10.453, p  =  0.004], 
post hoc p < 0.05}. RU486 treatment alone (no-SE + vehicle) had 
no effect on mossy cell numbers.
DiscUssiOn
The present study demonstrates that treatment with GR antago-
nist RU486 effectively blocks the SE-associated elevation of 
glucocorticoid levels in pilocarpine-treated mice, reduces hilar 
mossy cell loss, and mitigates cell proliferation in the HIL. Taken 
together, these findings indicate that GR blockade holds promise 
as a novel treatment for SE-induced brain injury.
The present findings extend prior work showing pronounced 
dysregulation of corticosterone levels following SE. Increased 
morning corticosterone secretion 24  h after SE has been 
observed previously (11), consistent with the current study. 
Here, we further demonstrate that SE-induced hypersecretion 
of corticosterone persists for at least 4 days but returns to base-
line by 7 days. These results reveal a transient initial phase of 
hypersecretion. Interestingly, elevated corticosterone secretion 
FigUre 2 | rU486 reduced mossy cell loss and hilar BrdU+ neurons in the hippocampus of post-se mice. (a) Micrograph depicting the regions analyzed: 
dentate granule cell body layer (DGC) and the hilus (HIL). Scale bar = 200 μm. (B) Micrograph showing examples of BrdU+ staining. Scale bars = 100 μm. (c) SE 
leads to an increased number of BrdU+ cells in the dentate hilus (**p < 0.01 main effect of SE). RU486 treatment reduced the number of BrdU+ cells in the dentate 
hilus of post-SE mice relative to vehicle-treated post-SE mice (*p < 0.05, RU486 different from vehicle within SE). (D) SE leads to an increase in BrdU+ cells in the 
dentate gyrus relative to control mice (**p < 0.01 main effect of SE). (e) SE leads to loss of GluR2+ cells in the dentate hilus relative to control mice (**p < 0.01, main 
effect of SE). RU486 treatment preserves greater numbers of GluR2+ cells in the dentate hilus of post-SE mice relative to their vehicle-treated counterparts 
(*p < 0.05, RU486 different from vehicle within SE). (F) Micrograph depicting GluR2 immunohistochemistry in the dentate hilus. Scale bars = 100 μm. All data 
presented as mean ± SEM, n = 6–8 mice.
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has also been observed in rats 6 weeks after SE (30). These find-
ings imply bimodal changes in corticosterone levels following 
SE, with early and late periods of hypersecretion.
Treatment with RU486 blocked the increase in corticosterone 
levels evident in untreated animals 4 days after SE. The mecha-
nism by which chronic RU486 treatment normalizes corticoster-
one levels is unknown. It has been hypothesized, however, that 
prolonged antagonism of GR may result in upregulation of the 
mineralocorticoid receptor in critical hypothalamic and limbic 
structures. Because RU486 has no affinity for the mineralocorti-
coid receptor (31), glucocorticoid binding to mineralocorticoid 
receptors in these stress-regulatory regions may induce reset-
ting of the HPA axis and reinstate control of baseline secretion 
(32–34). In addition, increased glucocorticoid binding to the 
mineralocorticoid receptor may oppose some of the toxic effects 
of GR binding (35, 36) and SE, thereby preserving key HPA axis 
feedback pathways.
In addition to actions on GR, RU486 also acts as a progester-
one receptor antagonist (31). Although we cannot exclude the 
possibility that progesterone receptor antagonism is important, 
we favor the interpretation that reduced hippocampal pathol-
ogy reflects GR antagonisms, as progesterone receptors are not 
widely expressed in the mouse hippocampus (37). Nonetheless, 
additional studies with more selective approaches will be needed 
to unambiguously rule out off-target effects.
RU486 treatment reduced mossy cell loss in the dentate 
HIL, suggesting that GR signaling during the hours and days 
following the insult may contribute to the development of 
hippocampal pathology. Findings are reminiscent of prior 
work showing that RU486 protects against CA1 neuronal loss 
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following traumatic brain injury (35). GR is expressed in all hip-
pocampal subfields and in mossy cells (38–40). Glucocorticoids, 
therefore, may act directly on vulnerable neurons to influence 
their survival. Alternatively, GR blockade on DGCs may 
indirectly reduce mossy cell loss. Glucocorticoids promote 
hypersecretion of glutamate by granule cell mossy fiber axons 
as early as 24  h following pilocarpine-induced SE, which can 
be blocked by treatment with RU486 (41). Granule cell axons 
directly innervate mossy cells and may contribute to excitotoxic 
loss of these neurons.
Status epilepticus results in large increases in cell proliferation, 
cell survival, and neurogenesis (42, 43). Consistent with these 
studies, post-SE mice had increased numbers of BrdU+ cells 
located in the subgranular zone and granule cell layer of the den-
tate gyrus. RU486 treatment did not have an effect in the number 
of BrdU+ cells in either of these regions. RU486 did, however, 
reduce the density of BrdU+ cells located in the dentate HIL. SE 
can induce astroglial and microglial proliferation in the HIL (44, 
45), as well as the accumulation of ectopic, newly generated gran-
ule cells (46–48). Reductions in cell proliferation in the HIL imply 
that RU486 mitigates some or all of these proliferative changes. 
Indeed, glucocorticoids have been implicated in regulating the 
migration, maturation, and functional integration of DGCs (49, 
50). Similarly, RU486 has been shown to prevent hippocampal 
astrogliosis in mice (51). Thus, glucocorticoid blockade following 
SE may prevent the aberrant migration of newborn granule cells 
into the dentate HIL and/or decrease astrogliosis.
Finally, it is important to note that RU486 administration to 
control mice did not alter any of the measures examined here and 
has been previously found to exert little impact on cell prolifera-
tion, survival, and inflammation in control subjects (32, 52–54). 
Our results are in agreement with other studies suggesting that 
the actions of RU486 may be specific to the pathological, high 
corticosterone environment (31). This specificity reflects the 
ability of RU486 to preferentially bind the GR over the mineralo-
corticoid receptor (31). Since GR’s are only fully occupied when 
corticosterone levels are elevated (55), the impact of blockade is 
most pronounced under these conditions.
cOnclUsiOn
The current study demonstrates that in the pilocarpine model 
of epilepsy, SE results in the rapid elevation of glucocorticoids. 
Treatment with the glucocorticoid antagonist RU486 following 
the insult blocks the SE-induced elevation of glucocorticoid 
baseline secretion, mitigates mossy cell loss, and reduces aber-
rant cell proliferation in the HIL. Our laboratory and others have 
implicated mossy cell loss and aberrant neuron proliferation in 
epileptogenesis, via mechanisms that result in hippocampal 
hyperexcitability (1–5). In addition, astrogliosis and brain 
inflammation are also associated with the pathophysiology 
of epilepsy (56). Together, our findings suggest that blockade 
of glucocorticoid signaling may be beneficial in preventing 
hippocampal damage following SE. To advance this line of 
investigation, it will be important in future studies to examine 
extended survival times so that the impact of RU486 on seizure 
frequency and animal behavior can be assessed. Time course 
studies to determine how long treatment can be delayed before 
it loses efficacy will also be important. Mossy cell loss may occur 
over days and weeks (57), but since this is a non-regenerative 
cell population, at some point loss will be irreversible. Finally, 
although the use of an FDA-approved drug like RU486 has 
obvious advantages for rapid translation, the use of more spe-
cific glucocorticoid receptor antagonists will be important to 
experimentally isolate glucocorticoid receptor-mediated from 
progesterone receptor-mediated effects.
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